Related references
Note: Only part of the references are listed.Enhancing endocrine response with novel targeted therapies - Why have the clinical trials to date failed to deliver on the preclinical promise?
Stephen R. D. Johnston et al.
CANCER (2008)
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
Elizabeth Iorns et al.
CANCER CELL (2008)
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
Suleiman Massarweh et al.
CANCER RESEARCH (2008)
Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
Danielle Meijer et al.
ENDOCRINE-RELATED CANCER (2008)
Short Preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
Marta Guix et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
ERBB2 status and outcome of endocrine treatment
W. R. Miller
LANCET ONCOLOGY (2008)
GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation
Tao Bai et al.
CARCINOGENESIS (2008)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer
Yago Nieto et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Concentrations of TIMPI mRNA splice variants and TIMP-I protein are differentially associated with prognosis in primary breast cancer
Anieta M. Sieuwerts et al.
CLINICAL CHEMISTRY (2007)
Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling
Randy S. Schrecengost et al.
CANCER RESEARCH (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs
Charles Swanton et al.
CANCER CELL (2007)
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Angelique W. Whitehurst et al.
NATURE (2007)
HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer:: A retrospective study
Maurice P. H. M. Jansen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/Neu and MMTV-polyoma middle T transgenic mice
Ioanna G. Maroulakou et al.
CANCER RESEARCH (2007)
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
G. R. Wilson et al.
BRITISH JOURNAL OF CANCER (2006)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone
Florence Gizard et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer
Patrick Urban et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes
Jessica Kao et al.
GENES CHROMOSOMES & CANCER (2006)
Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells
Danielle Meijer et al.
MOLECULAR CANCER RESEARCH (2006)
Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients
AM Sieuwerts et al.
CLINICAL CANCER RESEARCH (2006)
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer
JA Foekens et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes
MA Cobleigh et al.
CLINICAL CANCER RESEARCH (2005)
Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance
JS Lewis et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2005)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Retroviral insertional mutagenesis: past, present and future
AG Uren et al.
ONCOGENE (2005)
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study
AM Sieuwerts et al.
CLINICAL CANCER RESEARCH (2005)
AKT activation predicts outcome in breast cancer patients treated with tamoxifen
T Kirkegaard et al.
JOURNAL OF PATHOLOGY (2005)
Meningioma transcript profiles reveal deregulated notch signaling pathway
IC Cuevas et al.
CANCER RESEARCH (2005)
TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1
F Gizard et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer
JWM Martens et al.
CANCER RESEARCH (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
MPHM Jansen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The prognostic value of BCAR1 in patients with primary breast cancer
LCJ Dorssers et al.
CLINICAL CANCER RESEARCH (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer
LCJ Dorssers et al.
CLINICAL CHEMISTRY (2004)
TCF and Groucho-related genes influence pituitary growth and development
ML Brinkmeier et al.
MOLECULAR ENDOCRINOLOGY (2003)
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
R Clarke et al.
ONCOGENE (2003)
A gene-expression signature as a predictor of survival in breast cancer.
MJ van de Vijver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival
SS Bacus et al.
ONCOGENE (2002)
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
G Pérez-Tenorio et al.
BRITISH JOURNAL OF CANCER (2002)
Endocrine-responsive breast cancer and strategies for combating resistance
S Ali et al.
NATURE REVIEWS CANCER (2002)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells
A Brinkman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Bcar1/p130Cas protein and primary breast cancer: Prognosis and response to tamoxifen treatment
S van der Flier et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
